| COVID-19 DETECTION AND IMMUNE GENETIC VARIATION WITH CONSEQUENCE ON CLINICAL OUTCOME |
FRED HUTCHINSON CANCER RESEARCH CENTER |
National Institutes of Health |
September 21, 2016 |
None |
$528,451 |
| SUPPORT NATIONWIDE ACCESS TO ANTI-MALARIAL DRUGS BY EMERGENCY USE AUTHORIZATION (EUA) FOR HOSPITALIZED, SYMPTOMATIC ADULT AND ADOLESCENT PATIENTS CONFIRMED WITH SARS-COV-2 INFECTION, THE VIRUS WHICH CAUSES COVID-19 |
PPD DEVELOPMENT, L.P. |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 24, 2020 |
March 23, 2021 |
$0 |
| PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE |
National Institutes of Health |
March 27, 2020 |
May 31, 2021 |
$880,289 |
| COVID-19 |
UNIVERSITY OF MONTANA |
National Institutes of Health |
September 06, 2019 |
September 29, 2024 |
$2,499,879 |
| PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
SOUTHERN RESEARCH INSTITUTE |
National Institutes of Health |
March 27, 2020 |
May 26, 2021 |
$0 |
| REDS-IV-P DATA COORDINATING CENTER |
WESTAT, INC. |
National Institutes of Health |
April 01, 2019 |
March 31, 2021 |
$1,499,539 |
| REDS-IV-P CENTER FOR TRANSFUSION LABORATORY STUDIES PHASE 1 |
VITALANT |
National Institutes of Health |
April 01, 2019 |
March 31, 2021 |
$4,748,941 |
| ADJUVANT DISCOVERY PROGRAM |
VAXINE PTY LTD |
National Institutes of Health |
September 23, 2014 |
September 29, 2021 |
$500,000 |
| ADJUVANT DEVELOPMENT PROGRAM |
VIROVAX LLC |
National Institutes of Health |
September 30, 2018 |
September 29, 2023 |
$649,995 |
| PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
BATTELLE MEMORIAL INSTITUTE |
National Institutes of Health |
March 27, 2020 |
May 27, 2021 |
$1,094,669 |
| PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
BATTELLE MEMORIAL INSTITUTE |
National Institutes of Health |
March 27, 2020 |
May 27, 2021 |
$892,089 |
| PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE |
National Institutes of Health |
March 27, 2020 |
May 31, 2021 |
$1,453,431 |
| PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
SOUTHERN RESEARCH INSTITUTE |
National Institutes of Health |
March 27, 2020 |
May 26, 2021 |
$896,460 |
| AN EXPANDED ACCESS TREATMENT PROTOCOL FOR HYDROCHLOROQUINE AND CHLOROQUINE IN PATIENTS WITH CORONAVIRUS DISEASE (COVID-19), POSITIVE FOR SARS-COV-2 VIRUS EXPOSURE, OR PRE-EXPOSURE AND POST-EXPOSURE PROPHYLAXIS |
PPD DEVELOPMENT, L.P. |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 24, 2020 |
March 23, 2021 |
$750,000 |
| PCMID - ESTABLISHMENT OF SMALL ANIMAL MODELS FOR SCREENING MCMS FOR THE 2019 NOVEL CORONAVIRUS (SARS-COV-2) |
COLORADO STATE UNIVERSITY |
National Institutes of Health |
March 23, 2020 |
June 30, 2021 |
$320,414 |
| PRE-CLINICAL MODELS OF INFECTIOUS DISEASES - ESTABLISHMENT OF SMALL ANIMAL MODELS FOR SCREENING MCMS FOR THE 2019 NOVEL CORONAVIRUS (SARS-COV-2) |
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
National Institutes of Health |
March 23, 2020 |
November 30, 2021 |
$411,348 |
| THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE CLIN0002 AND IN RESPONSE TO THE PUBLIC HEALTH EMERGENCY FOR SARS-COV-2 TO ADD THE FOLLOWING CLINS: |
CUE INC. |
Office of Assistant Secretary for Preparedness and Response - HHS |
June 04, 2018 |
None |
$13,692,370 |
| PCMID - ESTABLISHMENT OF SMALL ANIMAL MODELS FOR SCREENING MCMS FOR THE 2019 NOVEL CORONAVIRUS (SARS-COV-2) |
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON |
National Institutes of Health |
March 23, 2020 |
March 22, 2021 |
$646,786 |
| PRE-CLINICAL MODELS OF INFECTIOUS DISEASES: ESTABLISHMENT OF SMALL ANIMAL MODELS FOR SCREENING MCMS FOR THE 2019 NOVEL CORONAVIRUS (SARS-COV-2) |
UTAH STATE UNIVERSITY |
National Institutes of Health |
March 29, 2021 |
March 28, 2022 |
$921,951 |